CTLA4 and neoplasm: Similarly, activation of CD152/ CTLA4 induces cell proliferation and tumor growth in lymphomas through activation of the TYK2-STAT3 pathway [67], and anti-CD152 mAb ipilimumab could be a potential targeted therapeutic for lymphomas [67,68].